Research

Trending/Research

Carfilzomib is not superior to Bortezomib in delaying multiple myeloma progression after initial treatment

ROCHESTER, Minn. ―  Carfilzomib, a proteasome inhibitor used in combination with Lenalidomide, an immune modulating drug, is not superior to Bortezomib, Lenalidomide and Dexamethasone, in the initial treatment of multiple myeloma according…

Sign up